Lucid Diagnostics (LUCD) Stock Forecast & Price Target

Lucid Diagnostics is positioned favorably because EsoGuard addresses a large, underpenetrated GERD screening population with a highly accurate, minimally invasive test and an estimated ~$2 billion domestic opportunity, while broader guideline inclusion across ACG, AGA, and NCCN strengthens its clinical legitimacy. The company’s outlook is further supported by tangible reimbursement momentum, including unanimous clinician support at the September 4, 2025 CAC meeting, first LBM coverage that opens over 10 million covered lives, and early commercial traction with three health plans and Highmark BCBS in May 2025. Financially, Q2'26 revenue rose 27% year over year to $1.5 million, cash ended at $33.4 million after $11 million of Q2 use, and liquidity appears sufficient into mid-2027, giving it runway to scale commercialization and pursue Medicare coverage.

Lucid Diagnostics is still in the early days of commercialization, but its Q1 2026 revenue was only $1.3 million versus a $10.5 million pro forma net loss, underscoring a business that is growing from a very small base while continuing to burn cash. Management also lowered 2026 revenue to $6.1 million and 2027 revenue to $23 million after a later-than-expected Medicare coverage decision, while Q1 EsoGuard tests fell to 3,177 from 3,664 in Q4 and 3,034 in Q1 2025. Although the addressable market is large, the outlook remains constrained by reimbursement dependence, deferred cash collection, and ongoing balance sheet, clinical utility, intellectual property, competition, and manufacturing risks.